Bioavailability, Pharmacokinetics, and Safety of Belimumab Administered Subcutaneously in Healthy Subjects
Authors:
- 26 August 2013
- journal article
- Published by Wiley in Clinical Pharmacology in Drug Development
- Vol. 2 (4) , 349-357
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Long‐term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosusArthritis & Rheumatism, 2012
- A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosusArthritis & Rheumatism, 2011
- Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trialThe Lancet, 2011
- A phase II, randomized, double‐blind, placebo‐controlled, dose‐ranging study of belimumab in patients with active systemic lupus erythematosusArthritis Care & Research, 2009
- Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosusArthritis Research & Therapy, 2008
- OmalizumabBioDrugs, 2008
- B cell depletion therapy in systemic lupus erythematosus: Effect on autoantibody and antimicrobial antibody profilesArthritis & Rheumatism, 2006
- AdalimumabBioDrugs, 2006
- Antibody Pharmacokinetics and PharmacodynamicsJournal of Pharmaceutical Sciences, 2004
- Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)Blood, 2002